Business Model
Business Model
Mucosis intends to bring its candidate vaccines into early phase clinical development leveraging non-dilutive funding where available. For later stage clinical development and marketing of our vaccines, we intend to further increase the value of our programs and products by collaborating with both international and local partners that have established a strong regulatory and business presence in the vaccine industry.
Drivers
Products with competitive advantages.
We have selected vaccine candidates that improve the currently available vaccines by means of patient friendliness and efficacy, and for which predictive animal models exist and/or correlates of protection in humans are well documented. The availability of models and correlates of protection shorten development timelines, reduce development risks and increase the chance for our products to hit the market. Our lead product FluGEM® is an intranasal influenza vaccine. We also run various vaccine research programs to identify new vaccine leads that can fill the product pipeline as with our SynGEM® vaccine candidate which targets respiratory syncytial virus disease.
Leveraging the value of our technology by licensing.
We have developed a plug & play vaccine technology that can be used to develop a portfolio of vaccine products. Therefore, we will license our technology to third parties for use in their in-house vaccine development programs. This will generate short term licensing revenue and future revenue from royalty on sales of the products that are developed with our technology. These revenues will be used to accelerate the development of Mucosis’s own in-house vaccine programs.